Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial

BACKGROUND: Given the persistently large public health impact of neovascular age-related macular degeneration (nARMD) despite many years of anti-VEGF therapy as the first-line treatment and the demonstrated ability of b-blockers to reduce neovascularization, a synergistic effect between an anti-VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva Tavares Neto, José Edísio da, Cyrino, Francyne Veiga Reis, Lucena, Moises Moura, Scott, Ingrid U., Messias, André Márcio Vieira, Jorge, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099020/
https://www.ncbi.nlm.nih.gov/pubmed/37055868
http://dx.doi.org/10.1186/s40942-023-00460-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099020/
https://www.ncbi.nlm.nih.gov/pubmed/37055868
http://dx.doi.org/10.1186/s40942-023-00460-1

Ejemplares similares